The startup develops RNA-only therapeutics that integrate genetic elements into safe harbor sites, enabling precise RNA-mediated insertion of transgenes. This approach addresses the need for targeted genetic medicine, offering patients a method for accurate and effective treatment options.
Funding
$81M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current gene therapy approaches often lack precise control over transgene insertion, leading to off-target effects and unpredictable expression levels. Existing methods may also trigger immune responses or insert genes into locations that disrupt essential cellular functions. This limits the safety and efficacy of genetic medicines.
Solution
Addition Therapeutics is developing RNA-only therapeutics that enable precise, RNA-mediated insertion of transgenes into safe harbor sites within the genome. Their PRINT™ technology allows targeted delivery and integration of genetic elements, minimizing the risk of off-target effects and ensuring stable, predictable transgene expression. This approach offers a more controlled and potentially safer method for genetic medicine, addressing the limitations of traditional gene therapy techniques.
Target Audience
The primary target audience includes patients with genetic disorders and pharmaceutical companies seeking advanced gene therapy solutions.
Features
- RNA-only therapeutics for targeted gene insertion
- PRINT™ technology enables precise integration at safe harbor sites
- Minimized off-target effects compared to traditional methods
- Stable and predictable transgene expression